Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level

Molecular and Cellular Neuroscience

Volumn 70, Issue , 2016, Pages 68-75

  Yang, Yan ^a   Ma, Delin ^a   Xu, Weijie ^a   Chen, Fuqiong ^a   Du, Tingting ^a   Yue, Wenzhu ^a   Shao, Shiying ^a   Yuan, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Blood brain barrier; Glucagon like peptide 1; Insulin signaling; Tau hyperphosphorylation; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAU PROTEIN; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HIPPOCAMPUS; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PEPTIDES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TAU PROTEINS; VENOMS;

EID: 84949196317     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2015.10.005     Document Type: Article

References (42)

1. Alexander G.M., Deitch J.S., Seeburger J.L., Del Valle L., Heiman-Patterson T.D. Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase. J. Neurochem. 2000, 74:1666-1673.
2. Aviles-Olmos I., Dickson J., Kefalopoulou Z., et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 2013, 123:2730-2736.
3. Aviles-Olmos I., Dickson J., Kefalopoulou Z., et al. Motor and cognitive advantages persist 12months after exenatide exposure in Parkinson's disease. J. Park. Dis. 2014, 4:337-344.
4. Banks W.A. The source of cerebral insulin. Eur. J. Pharmacol. 2004, 490:5-12.
5. Bataveljic D., Nikolic L., Milosevic M., Todorovic N., Andjus P.R. Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1(G93A) rat model. Glia 2012, 60:1991-2003.
6. Bloemer J., Bhattacharya S., Amin R., Suppiramaniam V. Impaired insulin signaling and mechanisms of memory loss. Prog. Mol. Biol. Transl. Sci. 2014, 121:413-449.
7. Boutajangout A., Wisniewski T. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Gerontology 2014.
8. Bruijn L.I., Becher M.W., Lee M.K., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
9. Coco M., Alagona G., Rapisarda G., Costanzo E., Calogero R.A., Perciavalle V., Perciavalle V. Elevated blood lactate is associated with increased motor cortex excitability. Somatosens. Mot. Res. 2010, 27:1-8.
10. Craft S., Baker L.D., Montine T.J., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
11. Dumont A.O., Hermans E., Goursaud S. Differential regulation of the glutamate transporter variants GLT-1a and GLT-1b in the cortex and spinal cord of transgenic rats expressing hSOD1(G93A). Neurochem. Int. 2013, 63:61-68.
12. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
13. Hernandez F., Lucas J.J., Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J. Alzheimers Dis. 2013, 33(Suppl. 1):S141-S144.
14. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012, 26:871-882.
15. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13:33.
16. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 2010, 7:656-664.
17. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
18. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci.: MN 2002, 18:7-14.
19. Kim M.Y., Lim J.H., Youn H.H., et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 2013, 56:204-217.
20. Lam D.W., LeRoith D. The worldwide diabetes epidemic. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19:93-96.
21. Liang N.C., Bello N.T., Moran T.H. Wheel running reduces high-fat diet intake, preference and mu-opioid agonist stimulated intake. Behav. Brain Res. 2015, 284:1-10.
22. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J. Neurochem. 2009, 111:242-249.
23. Liu C., Cholerton B., Shi M., Ginghina C., Cain K.C., Auinger P., Parkinson Study Group, D.I., Zhang J. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat. Disord. 2015, 21:271-276.
24. Messier C., Gagnon M. Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia 2009, 52:2471-2474.
25. Perry T., Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 2002, 4:487-496.
26. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
27. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
28. Rondas D., D'Hertog W., Overbergh L., Mathieu C. Glucagon-like peptide-1: modulator of beta-cell dysfunction and death. Diabetes Obes. Metab. 2013, 15(Suppl. 3):185-192.
29. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
30. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38:73-84.
31. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
32. Shao S., Nie M., Chen C., Chen X., Zhang M., Yuan G., Yu X., Yang Y. Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway. J. Cell. Biochem. 2014, 115:1166-1175.
33. Talbot K., Wang H.Y., Kazi H., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
34. Tolppanen A.M., Lavikainen P., Solomon A., Kivipelto M., Uusitupa M., Soininen H., Hartikainen S. History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study. Diabetes Care 2013, 36:2015-2019.
35. Trotti D., Rolfs A., Danbolt N.C., Brown R.H., Hediger M.A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 1999, 2:427-433.
36. Tweedie D., Rachmany L., Rubovitch V., et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp. Neurol. 2013, 239:170-182.
37. Van Den Bosch L., Van Damme P., Bogaert E., Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762:1068-1082.
38. van der Graaff M.M., Lavini C., Akkerman E.M., et al. MR spectroscopy findings in early stages of motor neuron disease. AJNR Am. J. Neuroradiol. 2010, 31:1799-1806.
39. Wu J., Nie S.D., Wang S. Tau pathology in diabetes mellitus. Pharmazie 2013, 68:649-652.
40. Yamamoto N., Matsubara T., Sobue K., Tanida M., Kasahara R., Naruse K., Taniura H., Sato T., Suzuki K. Brain insulin resistance accelerates Abeta fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J. Neurochem. 2012, 121:619-628.
41. Yang Y., Zhang J., Ma D., Zhang M., Hu S., Shao S., Gong C.X. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimers Dis. 2013, 37:637-648.
42. Yang Y., Moghadam A.A., Cordner Z.A., Liang N.C., Moran T.H. Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers. Endocrinology 2014, 155:3473-3483.